BC Innovations | May 4, 2017
Translation in Brief

Tethered hope

A Scripps team has developed a method for identifying antiviral, membrane-tethered antibodies that block virus-host receptor interactions without disrupting normal receptor functions, a strategy that could both reduce the ability of the virus to develop...
BC Week In Review | May 28, 2002
Clinical News

ING-1: Phase I

In an open-label, dose-ranging U.S. Phase I trial in 22 patients with advanced adenocarcinomas, dose-limiting adverse events including amylase and lipase elevations and abdominal pains occurred at 1 mg/kg. Adverse events occurring at ?0.3 mg/kg...
BioCentury | Apr 29, 2002

MorphoSys unveils its pipeline

German antibody specialist MorphoSys AG made good on its December promise to disclose plans this spring for moving into product development, adding infectious diseases to its previously announced areas of focus in oncology and inflammation....
BC Extra | Jun 25, 2001
Clinical News

Phase II data for ISIP in psoriasis

ISIP reported that its ISIS 2302 , a topical antisense inhibitor of Intercellular Adhesion Molecule -1 ( ICAM-1 ), showed a trend toward a relationship between compound concentration and reduction of plaque thickness, the study's primary end...
BC Week In Review | Nov 6, 2000
Clinical News

ING-1: Began Phase I trial

Xoma Ltd. (XOMA), Berkeley, Calif.   Product: ING-1   Business: Cancer   Therapeutic category: Antibody, Cytotoxic   Target: Ep-CAM intercellular adhesion molecule   Description: Humanized monoclonal antibody against the Ep-CAM epithelial cell antigen   Indication:...
BC Week In Review | Jan 12, 1998
Clinical News

Brigham and Women's Hospital preclinical data

Brigham and Women's Hospital , Boston, Mass., et al.  Product: Soluble intercellular adhesion molecule 1 (sICAM-1)  Indication: Predict risk of heart attack  Levels in plasma of sICAM-1 correlated to risk of heart attack in a study...
BC Week In Review | Dec 9, 1996
Clinical News

ISIS 2302 antisense inhibitor of intercellular adhesion molecule 1: Phase IIa trial

Isis Pharmaceuticals (ISIP), Carlsbad, Calif.   Product: ISIS 2302 antisense inhibitor of intercellular adhesion molecule 1 ( ICAM-1 )   Indication: Crohn's disease   Status: ISIP completed the first Phase IIa trial of ISIS 2302, triggering a...
Items per page:
1 - 7 of 7